Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ifosfamide and Doxorubicin in Refractory Nasopharyngeal Carcinoma
NCT00484601Phase 2
Key facts
- Status
- Terminated
- Start
- Apr 2004
- Primary completion
- Nov 2007
- Countries
- 1
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Modality
- DNA Intercalators/Alkylators
- Conditions
- nasopharyngeal carcinoma (NPC)
01
Overview
Phase 2, open-label, single-arm trial of ifosfamide and doxorubicin in nasopharyngeal carcinoma (NPC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoints: Overall Response Rate, Complete Response Rate and 3 more. Started Apr 2004; status: terminated.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Ifosfamide and Doxorubicin
Single arm treatment with Ifosfamide and Doxorubicin in patients with Refractory Nasopharyngeal Carcinoma
03
Who it enrols
Adults with histologically confirmed, measurable metastatic or recurrent nasopharyngeal carcinoma who have received exactly one prior chemotherapy regimen, with adequate organ and cardiac function.
04
Endpoints
Primary
Overall Response Rate
Complete Response Rate
Duration of Response
Time to Treatment Failure
Overall Survival
Secondary
Correlation of EBV DNA titer with clinical response
Beyond the preview
Go deeper on NCT00484601.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00484601.